DJIA 18,034.93 208.63 1.17%
NASDAQ 4,994.60 62.79 1.27%
S&P 500 2,100.40 19.22 0.92%
market minute promo

Roche Holding Ltd. (ADR) (NASDAQOTH: RHHBY)

35.62 0.18 (0.51%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

RHHBY $35.62 0.51%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $35.71
Previous Close $35.44
Daily Range $35.57 - $35.86
52-Week Range $32.08 - $38.15
Market Cap $200.2B
P/E Ratio 0.00
Dividend (Yield) $0.00 (2.3%)
Volume 338,991
Average Daily Volume 868,177
Current FY EPS $1.88





Roche Holding Ltd. (ADR) (RHHBY) Description


News & Commentary

Best Pure Play Investment in Cancer Drugs

Global cancer drug sales could soon soar past $100 billion, making this pure play in cancer drugs a stock you should seriously consider owning.

3 Promising Healthcare Stocks Under $10

Healthcare stocks with plenty of potential -- and low share prices

The Best Stock to Invest in Obesity Drugs

Making money helping people shed the pounds.

Could This Combo Therapy One Day Replace Chemotherapy?

Chemotherapy is a cancer treatment staple, but a recently published study suggests a combination of two treatments could provide the same benefit as chemotherapy with possibly far fewer side effects.

1 Small-Cap Biotech Stock to Buy and Hold For the Next 10 Years

Small cap biotech stocks have a lot of inherent risk, but if you can snag a winner your returns could double many times over. Here's one small-cap biotech stock you can consider buying and holding for the next 10 years.

3 Little-Known Biotechs Working On Potential Blockbusters

These three biotechs have promising drugs in their pipelines that address billion dollar drug markets.

This Tiny Biotech Offers Up New Hope for Parkinson's Disease Patients

Phase 1 trial results for Prothena Corporation's PRX-002 could indicate that this drug may help treat Parkinson's disease someday.

Why ImmunoGen Inc. is Soaring Higher Today

Takeda Pharmaceutical has licensed ImmunoGen's antibody-drug conjugate technology.

This Market Could Grow 6250% in 10 Years

With the regulatory pathway cleared, the biosimilars market is poised to turn into a gold mine, growing up to 6,250% in 10 years. Here's where to stake your claim.

Dividend Stocks: 2 to Avoid, 1 to Buy

Motley Fool contributor Todd Campbell offers up two dividend-paying healthcare stocks to avoid and one that could be a good buy for long-term income investors.

See More RHHBY News...

RHHBY's Top Competitors

RHHBY $35.62 (0.51%)
Current stock: RHHBY
PFE $35.01 (-0.09%)
Current stock: PFE
GSK $47.10 (-0.40%)
Current stock: GSK
NVS $102.24 (-0.21%)
Current stock: NVS